Biohaven Pharmaceuticals

Biohaven Pharmaceuticals

Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system.
 
Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company’s first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression.
 
Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.
 
Portage acquired a 54% equity share of Biohaven on January 6, 2014.  Subsequently, Biohaven has successfully raised several rounds of equity funding from third parties, and as a result, Portage's position in Biohaven was reduced to 35.85% on a fully diluted basis in July 2016. Since then, Biohaven has raised $80 million from third parties, further diluting Portage's position.

Biohaven Pharmaceuticals Board of Directors and Senior Management

  • Declan Doogan, MD

    Declan Doogan, MD

    Chairman and Director

    Dr. Declan Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice-President and Head of Worldwide Development at Pfizer, where many multibillion dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the US, the UK and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing Neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Declan is also an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and has also held professorships positions at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo). Declan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the UK.

  • Kamlesh Shah, CPA

    Kamlesh Shah, CPA

    Chief Financial Officer and Director

    Kam Shah is a senior finance executive with over 25 years of financial and management experience across a range of industries and companies with significant operating scale and complexity. Kam is a Certified Public Accountant and Chartered Global Management Accountant of the American Institute of CPAs and a Chartered Professional Accountant of the Canadian Institute of CPAs. He has experience in all aspects of corporate finance, including audits, SEC/OSC reporting, forecasting, and business plan development.

    Over the past 15 years, Kam has served as the Chief Financial Officer and Corporate Secretary of Bontan Corporation Inc., a publicly-listed group of companies engaged in biotechnology and oil and gas exploration.  Kam is also the Chief Financial Officer of SalvaRx Group PLC, and its subsidiary, iOx Therapeutics Ltd.

  • Greg Bailey, MD

    Greg Bailey, MD

    Director

    Gregory Bailey is a co-founder and managing partner of MediqVentures.

    Previously he was a managing partner of Palantir Group, Inc., a merchant bank involved in a number of biotech company startups and financings. Palantir was also involved in acquiring intellectual property assets and founding companies around the IP.

    As such Greg was the co-founder of Ascent Healthcare Solutions, VirnetX Inc. (VHC:AMEX), Portage Biotech Inc. (PTGEF: OTCBB) and DuraMedic Inc. He was the initial financier and an independent director of Medivation, Inc. (MDVN:NASDAQ), from 2005 to December 2012.

    Dr. Bailey served as the Managing Director and co-Head of Life Sciences at MDB Capital Group LLC from May 2004 to December 2006.

    Greg has served on the board of directors of multiple public companies.

    Greg practiced emergency medicine for 10 years before entering finance. He received his medical degree from the University of Western Ontario.

  • John W Childs

    John W Childs

    Director

    Mr. John W. Childs serves as the Chairman and Partner of J.W. Childs Associates, L.P., a private equity firm. He co-founded J.W. Childs Associates in 1995. Prior to founding J.W. Childs Associates, Mr. Childs was Senior Managing Director of the Thomas H. Lee Company from 1991 to 1995. In this capacity, he had broad responsibilities for originating, analyzing, negotiating and managing leveraged buyout transactions for the THL funds. For seventeen years prior to joining THL, Mr. Childs was with the Prudential Insurance Company of America where he held various executive positions in the investment area, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. He is currently Chairman of Sunny Delight and a director of Kosta Browne, Esselte, Mattress Firm, WS Packaging and SIMCOM. Prior to its sale, he was Chairman of the Board of CHG Healthcare Services. Mr. Childs has a B.A. from Yale University and a M.B.A. from Columbia University.

  • Vlad Coric, MD

    Vlad Coric, MD

    Chief Executive Officer and Director

    Dr. Coric has more than 15 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb. Within the pharmaceutical industry, Dr. Coric has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Most recently, Dr. Coric was the immuno-oncology indication lead for neuro-oncology and glioblastoma. He has been involved in multiple drug development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). He has conducted numerous clinical trials in various illnesses including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, hepatocellular carcinoma, and glioblastoma. Dr. Coric was the first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders (Coric et al., 2003; 2005; Sanacora et al., 2004) and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer’s Disease while at Bristol-Myers Squibb (Coric et al 2015). Additionally, Dr. Coric spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. Dr. Coric is an Associate Clinical Professor of Psychiatry at the Yale School of Medicine and has over 50 peer-reviewed publications. He previously served as Chief of the Yale Clinical Neuroscience Research Unit, and Director of the Yale Obsessive-Compulsive Disorder Research Clinic. He has served as President of the Connecticut Psychiatric Society (an 800 member district branch of the American Psychiatric Association). Dr. Coric completed residency training at the Yale Psychiatry Residency Training Program, where he also served as the Program-Wide Chief Resident for the Yale Department of Psychiatry, and Chief Resident on the PTSD firm at the West-Haven Connecticut Veterans Administration Hospital. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina.